These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25208876)

  • 21. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
    Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
    Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chitosan-Coated Lipid-Core Nanocapsules Functionalized with Gold-III and Bevacizumab Induced In Vitro Cytotoxicity against C6 Cell Line and In Vivo Potent Antiangiogenic Activity.
    de Cristo Soares Alves A; Lavayen V; Figueiró F; Dallemole DR; de Fraga Dias A; Cé R; Battastini AMO; Guterres SS; Pohlmann AR
    Pharm Res; 2020 May; 37(6):91. PubMed ID: 32385723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laronidase.
    BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
    Giugliani R; Rojas VM; Martins AM; Valadares ER; Clarke JT; Góes JE; Kakkis ED; Worden MA; Sidman M; Cox GF
    Mol Genet Metab; 2009 Jan; 96(1):13-9. PubMed ID: 19038563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
    Xue Y; Richards SM; Mahmood A; Cox GF
    Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemocompatibility of poly(ɛ-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan.
    Bender EA; Adorne MD; Colomé LM; Abdalla DSP; Guterres SS; Pohlmann AR
    Int J Pharm; 2012 Apr; 426(1-2):271-279. PubMed ID: 22322210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laronidase treatment of mucopolysaccharidosis I.
    Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
    BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
    Turner CT; Hopwood JJ; Brooks DA
    Mol Genet Metab; 2000 Apr; 69(4):277-85. PubMed ID: 10870845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c.1898C>G/p.Ser633Trp Mutation in Alpha-L-Iduronidase: Clinical and Structural Implications.
    Peña-Gomar I; Jiménez-Mariscal JL; Cerón M; Rosas-Trigueros J; Reyes-López CA
    Protein J; 2021 Feb; 40(1):68-77. PubMed ID: 33389473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression.
    Munoz-Rojas MV; Vieira T; Costa R; Fagondes S; John A; Jardim LB; Vedolin LM; Raymundo M; Dickson PI; Kakkis E; Giugliani R
    Am J Med Genet A; 2008 Oct; 146A(19):2538-44. PubMed ID: 18792977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
    Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
    BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
    Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
    Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
    Thomas JA; Jacobs S; Kierstein J; Van Hove J
    J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
    Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
    J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
    Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
    Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
    J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-L-iduronidase (laronidase; aldurazyme).
    Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
    [No Abstract]   [Full Text] [Related]  

  • 39. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
    Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
    J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.